Literature DB >> 17876005

Novel drug resistance pattern associated with the mutations K70G and M184V in human immunodeficiency virus type 1 reverse transcriptase.

D Bradshaw1, S Malik, C Booth, M Van Houtte, T Pattery, A Waters, J Ainsworth, A M Geretti.   

Abstract

We describe an unusual pathway of human immunodeficiency virus type 1 reverse transcriptase resistance during therapy with tenofovir-emtricitabine, characterized initially by the mutations K70E and M184V and later by K70G and M184V, with the two mutations coexisting on the same viral genome. Phenotypic resistance to lamivudine, emtricitabine, abacavir, didanosine, and tenofovir was observed, whereas susceptibility to zidovudine and stavudine was preserved.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17876005      PMCID: PMC2167988          DOI: 10.1128/AAC.00687-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

1.  Selection of a rare resistance profile in an HIV-1-infected patient exhibiting a failure to an antiretroviral regimen including tenofovir DF.

Authors:  Constance Delaugerre; Laurent Roudiere; Gilles Peytavin; Christine Rouzioux; Jean-Paul Viard; Marie-Laure Chaix
Journal:  J Clin Virol       Date:  2005-03       Impact factor: 3.168

2.  Novel mutation (K70E) in human immunodeficiency virus type 1 reverse transcriptase confers decreased susceptibility to 9-[2-(phosphonomethoxy)ethyl]adenine in vitro.

Authors:  J M Cherrington; A S Mulato; M D Fuller; M S Chen
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

3.  Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903.

Authors:  N A Margot; B Lu; A Cheng; M D Miller
Journal:  HIV Med       Date:  2006-10       Impact factor: 3.180

4.  In vitro selection and analysis of human immunodeficiency virus type 1 resistant to derivatives of beta-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine.

Authors:  Jennifer L Hammond; Urvi M Parikh; Dianna L Koontz; Susan Schlueter-Wirtz; Chung K Chu; Hengameh Z Bazmi; Raymond F Schinazi; John W Mellors
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

5.  Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors.

Authors:  Nicolas Sluis-Cremer; Chih-Wei Sheen; Shannon Zelina; Pedro S Argoti Torres; Urvi M Parikh; John W Mellors
Journal:  Antimicrob Agents Chemother       Date:  2006-11-06       Impact factor: 5.191

6.  Human immunodeficiency virus type 1 reverse transcriptase expressing the K70E mutation exhibits a decrease in specific activity and processivity.

Authors:  M D Miller; P D Lamy; M D Fuller; A S Mulato; N A Margot; T Cihlar; J M Cherrington
Journal:  Mol Pharmacol       Date:  1998-08       Impact factor: 4.436

7.  Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy.

Authors:  A S Mulato; P D Lamy; M D Miller; W X Li; K E Anton; N S Hellmann; J M Cherrington
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

  7 in total
  6 in total

Review 1.  HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.

Authors:  Robert W Shafer; Jonathan M Schapiro
Journal:  AIDS Rev       Date:  2008 Apr-Jun       Impact factor: 2.500

2.  Nonpolymorphic human immunodeficiency virus type 1 protease and reverse transcriptase treatment-selected mutations.

Authors:  Rajin Shahriar; Soo-Yon Rhee; Tommy F Liu; W Jeffrey Fessel; Anthony Scarsella; William Towner; Susan P Holmes; Andrew R Zolopa; Robert W Shafer
Journal:  Antimicrob Agents Chemother       Date:  2009-08-31       Impact factor: 5.191

3.  Formation of a quaternary complex of HIV-1 reverse transcriptase with a nucleotide-competing inhibitor and its ATP enhancer.

Authors:  Maryam Ehteshami; Monique Nijhuis; Jean A Bernatchez; Christopher J Ablenas; Suzanne McCormick; Dorien de Jong; Dirk Jochmans; Matthias Götte
Journal:  J Biol Chem       Date:  2013-04-18       Impact factor: 5.157

4.  Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibility.

Authors:  George L Melikian; Soo-Yon Rhee; Jonathan Taylor; W Jeffrey Fessel; David Kaufman; William Towner; Paolo V Troia-Cancio; Andrew Zolopa; Gregory K Robbins; Ron Kagan; Dennis Israelski; Robert W Shafer
Journal:  Antimicrob Agents Chemother       Date:  2012-02-13       Impact factor: 5.191

Review 5.  Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost?

Authors:  Christopher B Hurt; Joseph J Eron; Myron S Cohen
Journal:  Clin Infect Dis       Date:  2011-10-05       Impact factor: 9.079

6.  Temporal Trends in HIV-1 Mutations Used for the Surveillance of Transmitted Drug Resistance.

Authors:  Soo-Yon Rhee; Philip L Tzou; Robert W Shafer
Journal:  Viruses       Date:  2021-05-11       Impact factor: 5.048

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.